June 18, 2025
Operating Assets

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid …

Research and Development Expenses: $39.4 million for the fiscal year ended March 31, 2025, up from $20 million the previous year. General and Administrative Expenses: $17.1 million for the fiscal year ended March 31, 2025, compared to $14.1 million the previous year. Net Loss: $51.4 million for the fiscal year ended March 31, 2025, compared

Read More
Operating Assets

Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges

Q: How is the pace and quality of enrollment in Asia compared to the US? A: The pace of enrollment in Asia is about 2 to 4 times faster than in the US. The sites in Asia ramped up faster, and in the past few months, the output from Asia has matched that of the

Read More